Tetrahydrocannabivarin (THCV) Research Dashboard
Studies by Organ System
No data to display
Studies by Country of Researcher
No data to display
Top Conditions Related to THCV Studies
No data to display
Receptors Associated with THCV Studies
No data to display
There Is Clinical Evidence Using THCV for These Conditions:
Page Quick Links
Select New Cannabinoid
49 PRIMARY STUDIES | 83 TOTAL STUDIES
Cross-substance primed and cue-induced craving among alcohol and cannabis co-users: An experimental psychopharmacology approach
Effects of cannabinoids on resting state functional brain connectivity: A systematic review
Molecular pathway and structural mechanism of human oncochannel TRPV6 inhibition by the phytocannabinoid tetrahydrocannabivarin
Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users
Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents
Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes
A Systematic Review of Medical Cannabinoids Dosing in Human
Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort
Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice
Screening and confirmation methods for the qualitative identification of nine phytocannabinoids in urine by LC-MS/MS
Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment
Specific Compositions of Cannabis sativa Compounds Have Cytotoxic Activity and Inhibit Motility and Colony Formation of Human Glioblastoma Cells In Vitro
The Cannabinoids Tetrahydrocannabinol, Cannabinol, Cannabidiol, Tetrahydrocannabivarin, and 11-nor-9-carboxy-∆9-THC in Hair
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice
Detectability of cannabinoids in the serum samples of cannabis users: Indicators of recent cannabis use? A follow-up study
Biomarkers of Recent Cannabis Use in Blood, Oral Fluid and Breath
Fast liquid chromatography-tandem mass spectrometry method for the simultaneous determination of phytocannabinoids in oily based preparations
Cannabis sativa as a Treatment for Obesity: From Anti-Inflammatory Indirect Support to a Promising Metabolic Re-Establishment Target
Identification and quantification of cannabinoids in postmortem fluids and tissues by liquid chromatography-tandem mass spectrometry
Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis
An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models
Δ9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats
Beneficial effects of the phytocannabinoid Δ 9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
Antioxidant and antimicrobial activity of two standardized extracts from a new Chinese accession of non-psychotropic Cannabis sativa L
Synthesis of the Major Mammalian Metabolites of THCV
Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes
Cannabinoids and Chronic Liver Diseases
High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain
Validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to detect cannabinoids in whole blood and breath
Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence
Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders
Effects of non‐euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice
The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers
The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.
The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers
The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.
Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile
Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats
Δ8-Tetrahydrocannabivarin Prevents Hepatic Ischaemia/Reperfusion Injury by Decreasing Oxidative Stress and Inflammatory Responses Through Cannabinoid CB2 Receptors
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum
The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo
Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study
Cannabivarin and Tetrahydrocannabivarin, Two New Constituents of Hashish
34 RELATED STUDIES | 83 TOTAL STUDIES
Profiling Cannabinoid Contents and Expression Levels of Corresponding Biosynthetic Genes in Commercial Cannabis (Cannabis sativa L.) Cultivars
Cannabis for Medical Use: Versatile Plant Rather Than a Single Drug
Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations
Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review
Cannabis sativa Extract Induces Apoptosis in Human Pancreatic 3D Cancer Models: Importance of Major Antioxidant Molecules Present Therein
Cannabis Use and the Endocannabinoid System: A Clinical Perspective
A Review on the Bioactivity of Cannabinoids on Zebrafish Models: Emphasis on Neurodevelopment
The Medicinal Natural Products of Cannabis sativa Linn.: A Review
Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer
In vitro percutaneous absorption studies of cannabidiol using human skin: Exploring the effect of drug concentration, chemical enhancers, and essential oils
Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC
Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Actions of Phytocannabinoids or Endocannabinoids on TRPA1 and TRPV1 Channels
Identification of Chemotypic Markers in Three Chemotype Categories of Cannabis Using Secondary Metabolites Profiled in Inflorescences, Leaves, Stem Bark, and Roots
Development and Optimization of Supercritical Fluid Extraction Setup Leading to Quantification of 11 Cannabinoids Derived from Medicinal Cannabis
Differential Interactions of Selected Phytocannabinoids with Human CYP2D6 Polymorphisms
Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions
Quantitation of Δ8-THC, Δ9-THC, Cannabidiol, and Ten Other Cannabinoids and Metabolites in Oral Fluid by HPLC-MS/MS
Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages
The Current and Potential Application of Medicinal Cannabis Products in Dentistry
It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets
Cannabinoids and Cannabinoid Receptors: The Story so Far
In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa
Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets
Future Aspects for Cannabinoids in Breast Cancer Therapy
Simultaneous Quantification of 13 Cannabinoids and Metabolites in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry in Adult Epilepsy Patients
Potential Mechanisms Influencing the Inverse Relationship Between Cannabis and Nonalcoholic Fatty Liver Disease: A Commentary
Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome
Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System
Molecular Targets of the Phytocannabinoids-A Complex Picture
Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake
Non-THC Cannabinoids Inhibit Prostate Carcinoma Growth In Vitro And In Vivo: Pro-apoptotic Effects And Underlying Mechanisms
Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.
Modulation of l-α-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin
Overview - Tetrahydrocannabivarin (THCV)
Description of Tetrahydrocannabivarin (THCV)
Δ-9-Tetrahydrocannabivarin (Δ-9-THCV) was discovered in 1969 (F. Merkus 1971).
THCV belongs to the THC group but produces significantly different effects than THC. This difference in effect is largely due to their different effects at CB1. THC is an agonist at CB1, while THCV is an antagonist at the same receptor and, as such, induces opposing effects. For instance, while THC can induce euphoria, THCV can produce dysphoria. THC increases appetite ("the munchies"), while THCV decreases the desire for food.
A lot of attention has been given to THCV of late due to the observation that it may be able to induce several therapeutic effects in patients challenged by metabolic syndrome, obesity, and diabetes. This is especially true in the context of the failed approach with Rimonabant (a full CB1 antagonist with a Ki of ~2nM) used extensively to induce weight loss but pulled from the EU market due to associated mood disorders, including suicidal ideations.
Δ(8) -THCV (is a synthetic analog of the plant cannabinoid Δ(9) -THCV.
Here we focus primarily on Δ-9-THCV.
Other Names:
Delta 9-TetrahydrocannabivarinTHCV, THC-V, Delta-9-Tetrahydrocannabivarin, Δ-9-Tetrahydrocannabivarin, plus numerous other supplier-based synonyms.
IUPAC Name: (6aR,10aR)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
Molecular Formula: C19H26O2
Source–PubChem
Tetrahydrocannabivarin (THCV) Properties and Effects
Δ-9-THCV may induce the following properties and effects:
- Analgesia
- Inflammatory pain (reduction) (D. Bolognini et al., 2010)
- Paclitaxel-induced peripheral neuropathy (reduction) (A. Kavala et al., 2022)
- Anti-addictive (cannabis) (E. Galaj et al., 2019)
- Anti-addictive (opioids) (E. Galaj et al., 2019)
- Anti-diabetic
- Adiponectin (improved function of this natural hormone that helps to regulate glucose levels) (K. Jadoon et al., 2016)
- Insulin sensitivity (improved) (E. Wargent et al., 2013)
- Glucose levels (decrease plasma glucose concentrations) (K. Jadoon et al., 2016)
- Pancreatic beta-cell (improved function) (K. Jadoon et al., 2016)
- Anti-cancer (A. Neuberger et al., 2023)
- Anti-dyskinesia (Δ-9-THCV reduced L-DOPA-induced dyskinesia) (I. Espadas et al., 2020)
- Anti-epileptic (A. Hill et al., 2010)
- Anti-nausea (E. Rock et al., 2013)
- Anti-obesity (E. Wargent et al., 2013)
- Antioxidant (C. Garcia et al., 2011)
- Anti-psychotic (potentially beneficial effects via serotonin receptor site activation) (M. Cascio et al., 2015)
- Appetite-suppressant (A. Abioye et al., 2020)
- Dysphoric (full antagonists at CB1 have been shown to induce dysphoric effects-see SR-141716A) (R. Christensen et al., 2007; F. Akbas et al., 2009)
- Neuroprotective (C. Garcia et al., 2011)
- Antimicrobial (i.e., effective against MRSA)
Δ-8-THCV may:
- Anti-addictive (nicotine) (Z. Xi. et al., 2019)
Adverse Effects of THCV:
Clinical data regarding the potential adverse effects of CBN remains wanting. However, since THCV is a full antagonist at CB1, some researchers remain concerned about possible dysphoric effects.
Tetrahydrocannabivarin (THCV) Receptor Binding
The endocannabinoid system (ECS) and THCV:
- CB1 antagonist with a mean Ki of ~84nM using data from 5 trials (J. McPartland et al., 2015); in contrast, Rimonabant (aka SR-141716A) is a full CB1 antagonist with a Ki of ~2nM (M. Rinaldi-Carmona et al., 1994).
- THCV is an inhibitor of CB1 agonists (e.g., reduced THC-associated increases in heart rate, decrease in THC-associated psychoactivity) while increasing others, i.e., significantly increased memory intrusions
- CB2 agonist with a mean Ki of ~125nM using data from 3 trials (J. McPartland et al., 2015)
Endocannabinoidome (eCBome) and THCV:
- GPR-55 (Mixed results, THCV acted as an agonist/antagonist (E. Wargent et al., 2020)
- TRPV6 (potential inhibitor) (A. Neuberger et al., 2023)
- Serotonin receptor sites
- 5-HT1A (may act as a positive allosteric modulator) (M. Cascio et al., 2015)
Ki legend:
- Full/strong agonist Ki ~1-9nM
- Moderate agonist Ki ~10-99nM
- Weak agonist Ki ~100-999nM
- Very weak agonist Ki ~1,000-up nM
(The reader is reminded that a smaller Ki is associated with the strongest effects.)
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
